William Blair analyst Margaret Kaczor has maintained their neutral stance on SGHT stock, giving a Hold rating on March 4.
Margaret Kaczor’s rating is based on a combination of factors affecting Sight Sciences’ financial outlook. The company’s fourth-quarter sales were slightly below expectations, primarily due to headwinds from the final local coverage determination impacting multiple MIGS procedures. This has led to a slower growth in surgical glaucoma, which is a significant part of Sight Sciences’ business. The company anticipates these challenges to persist through 2025 as surgeons adjust their treatment strategies.
Additionally, while there is potential in the dry eye market, current sales are low due to the increased cash-pay price and the lack of full reimbursement for TearCare. Although management is optimistic about future coverage decisions and the long-term market opportunity, significant sales growth is not expected until 2026. The company’s guidance for 2025 also reflects a decline in revenue, which further supports the Hold rating as investors await clearer signs of recovery and growth.
In another report released on March 4, Citi also maintained a Hold rating on the stock with a $3.00 price target.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SGHT in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com